CORV - Correvio Pharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.07
-0.02 (-0.65%)
As of 10:02AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.09
Open3.08
Bid3.07 x 1000
Ask3.13 x 1300
Day's Range3.07 - 3.08
52 Week Range1.31 - 5.24
Volume610
Avg. Volume180,366
Market Cap112.208M
Beta (3Y Monthly)-0.56
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.91
Trade prices are not sourced from all markets
  • CNW Group8 days ago

    Correvio Reports Third Quarter 2018 Financial Results

    Correvio Reports Third Quarter 2018 Financial Results

  • PR Newswire8 days ago

    Correvio Reports Third Quarter 2018 Financial Results

    Management to Host Conference Call and Webcast Today, November 6, 2018 at 4:30 p.m. Eastern ( 1:30 p.m. Pacific) NASDAQ: CORV  TSX: CORV VANCOUVER , Nov. 6, 2018 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: ...

  • Zacks Small Cap Research14 days ago

    CORV: Brinavess Continues to Hit Milestones

    2018 has been an exciting year for Correvio Pharma Corp. (CORV) (CORV.TO), with several transformative events taking place. Brinavess continues to achieve milestones with the recent conclusion of the pre-NDA meeting, confirmation of the timeline for FDA action and receipt of an opinion regarding an extension of the patent term. The most exciting news for the year was the FDA’s announcement regarding the resubmission of Brinavess and the scheduling of a pre-NDA meeting.

  • CNW Group15 days ago

    Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018

    Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018

  • PR Newswire16 days ago

    Correvio Announces Brinavess Eligibility for Patent Extension

    VANCOUVER, Oct. 29, 2018 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that it has received independent regulatory and legal opinions that Brinavess® (vernakalant hydrochloride, IV) may qualify for up to a 5-year patent extension from the U.S. Patent and Trademark Office (USPTO). Brinavess® is Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), for which it will be resubmitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the second quarter of 2019.

  • CNW Group16 days ago

    Correvio Announces Brinavess Eligibility for Patent Extension

    VANCOUVER , Oct. 29, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that it has received independent regulatory and legal opinions that Brinavess® (vernakalant hydrochloride, IV) may qualify for up to a 5-year patent extension from the U.S. Patent and Trademark Office (USPTO). Brinavess® is Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), for which it will be resubmitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the second quarter of 2019.

  • PR Newswire22 days ago

    Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019

    VANCOUVER, Oct. 23, 2018 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that, based on productive pre-NDA discussions with the U.S. Food and Drug Administration (FDA), Correvio plans to resubmit the Brinavess® (vernakalant hydrochloride, IV) New Drug Application (NDA) during the second quarter of 2019.  Brinavess® is Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF).  The FDA agreed that no additional studies would be required for the resubmission of the NDA.

  • CNW Group22 days ago

    Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019

    VANCOUVER , Oct. 23, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that, based on productive pre-NDA discussions with the U.S. Food and Drug Administration (FDA), Correvio plans to resubmit the Brinavess® (vernakalant hydrochloride, IV) New Drug Application (NDA) during the second quarter of 2019.  Brinavess® is Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF).  The FDA agreed that no additional studies would be required for the resubmission of the NDA.

  • Zacks Small Cap Researchlast month

    CORV: Brinavess Continues to Lead

    Correvio Pharma Corp. (CORV) has had an exciting year for Brinavess so far in 2018. While it received EMA regulatory approval in 2010, it was not given the go ahead in the United States and has been on hold with the FDA ever since. Despite the hold, things have begun to turn in favor of Brinavess on several fronts.

  • PR Newswire2 months ago

    Correvio to Participate In Upcoming Investor Conferences

    NASDAQ: CORV   TSX: CORV VANCOUVER , Sept. 20, 2018 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, ...

  • CNW Group2 months ago

    Correvio to Participate In Upcoming Investor Conferences

    Correvio to Participate In Upcoming Investor Conferences

  • PR Newswire2 months ago

    Correvio Reports Preliminary Data Collected from 2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study

    VANCOUVER, Sept. 5, 2018 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported preliminary data from SPECTRUM, a post-authorization safety study evaluating Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), conducted in the European Union (EU). SPECTRUM was conducted as part of the follow-up measures agreed to with the European Medicines Agency in 2010.

  • CNW Group2 months ago

    Correvio Reports Preliminary Data Collected from 2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study

    VANCOUVER , Sept. 5, 2018 /CNW/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported preliminary data from SPECTRUM, a post-authorization safety study evaluating Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), conducted in the European Union (EU). SPECTRUM was conducted as part of the follow-up measures agreed to with the European Medicines Agency in 2010.

  • CNW Group2 months ago

    Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics

    VANCOUVER , Sept. 4, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today highlighted that United Therapeutics (UTHR) has completed its acquisition of SteadyMed Ltd., Correvio's partner and the licensor of Trevyent®.

  • PR Newswire2 months ago

    Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics

    VANCOUVER, Sept. 4, 2018 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today highlighted that United Therapeutics (UTHR) has completed its acquisition of SteadyMed Ltd., Correvio's partner and the licensor of Trevyent®.

  • Investopedia2 months ago

    Penny Stocks to Watch for September 2018

    Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.

  • CNW Group3 months ago

    Correvio to Participate in Upcoming Investor Conferences

    Correvio to Participate in Upcoming Investor Conferences

  • PR Newswire3 months ago

    Correvio to Participate in Upcoming Investor Conferences

    NASDAQ: CORV   TSX: CORV       VANCOUVER , Aug. 28, 2018 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, ...

  • PR Newswire3 months ago

    Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients

    VANCOUVER, Aug. 16, 2018 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported positive data highlighting reduced hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF in Belgian hospitals. As a result of this new, real world data, Brinavess received reimbursement approval from the National Institute for Health and Disability Insurance (NIHDI) in Belgium. The data from this survey, which was mandated by the NIHDI, was provided by six participating hospitals in Belgium, across a total of 97 patients that were treated with Brinavess in the emergency room setting for a total of 15.5 months during 2017 and 2018. The data demonstrated that treatment with Brinavess successfully avoided hospitalization for 85.4% (95% confidence interval [CI] 76.1 – 94.8) of all treated patients. Treatment with Brinavess also significantly decreased the use of electric cardioversion, with 84.1% (95% CI 71.5 – 96.7) of patients avoiding electric cardioversion and all adverse events related to this procedure.

  • CNW Group3 months ago

    Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients

    VANCOUVER , Aug. 16, 2018 /CNW/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported positive data highlighting reduced hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF in Belgian hospitals. As a result of this new, real world data, Brinavess received reimbursement approval from the National Institute for Health and Disability Insurance (NIHDI) in Belgium . The data from this survey, which was mandated by the NIHDI, was provided by six participating hospitals in Belgium , across a total of 97 patients that were treated with Brinavess in the emergency room setting for a total of 15.5 months during 2017 and 2018. The data demonstrated that treatment with Brinavess successfully avoided hospitalization for 85.4% (95% confidence interval [CI] 76.1 – 94.8) of all treated patients. Treatment with Brinavess also significantly decreased the use of electric cardioversion, with 84.1% (95% CI 71.5 – 96.7) of patients avoiding electric cardioversion and all adverse events related to this procedure.

  • PR Newswire3 months ago

    Correvio Reports Second Quarter 2018 Financial Results

    Management to Host Conference Call and Webcast Today,  August 14, 2018 at 4:30 p.m. Eastern ( 1:30 p.m. Pacific) NASDAQ: CORV  TSX: CORV VANCOUVER , Aug. 14, 2018 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: ...

  • CNW Group3 months ago

    Correvio Reports Second Quarter 2018 Financial Results

    Correvio Reports Second Quarter 2018 Financial Results

  • ACCESSWIRE3 months ago

    Cardiome Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Cardiome Pharma Corp. (NASDAQ: CORV ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern ...

  • PR Newswire3 months ago

    Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China

    VANCOUVER, Aug. 14, 2018 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today announced that Brinavess®  (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), was selected by the China Food and Drug Administration's (CFDA) Center for Drug Evaluation (CDE) as potentially eligible for priority review.  In the list published last week by the CDE, Brinavess was named one of 48 therapies assessed as "clinically urgently needed new drugs", and therefore eligible under the priority review pathway. In addition to clinical trial data supporting Brinavess' ex-China regulatory approvals, Correvio will also be expected to provide evidence that there are no differences in Brinavess' efficacy or safety across ethnicities. The Brinavess clinical data package includes positive results from a Phase 3 trial evaluating Brinavess in AF patients (n=123) which was conducted in Korea, Taiwan, Hong Kong and India.  In addition to this trial, Correvio's partner Eddingpharm (Asia) Macao Commercial Offshore Limited recently initiated a randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating Brinavess versus placebo in patients with recent onset AF.  Approximately 240 patients are expected to be enrolled at an estimated 30 clinical trial sites in China.  If a New Drug Application (NDA) is accepted for priority review in China, the average length of time to approval is approximately 60 business days.

  • CNW Group3 months ago

    Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China

    VANCOUVER , Aug. 14, 2018 /CNW/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today announced that Brinavess®  (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), was selected by the China Food and Drug Administration's (CFDA) Center for Drug Evaluation (CDE) as potentially eligible for priority review.  In the list published last week by the CDE, Brinavess was named one of 48 therapies assessed as "clinically urgently needed new drugs", and therefore eligible under the priority review pathway. In addition to clinical trial data supporting Brinavess' ex- China regulatory approvals, Correvio will also be expected to provide evidence that there are no differences in Brinavess' efficacy or safety across ethnicities. The Brinavess clinical data package includes positive results from a Phase 3 trial evaluating Brinavess in AF patients (n=123) which was conducted in Korea, Taiwan , Hong Kong and India .  In addition to this trial, Correvio's partner Eddingpharm ( Asia ) Macao Commercial Offshore Limited recently initiated a randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating Brinavess versus placebo in patients with recent onset AF.  Approximately 240 patients are expected to be enrolled at an estimated 30 clinical trial sites in China.  If a New Drug Application (NDA) is accepted for priority review in China , the average length of time to approval is approximately 60 business days.